PMCB
insider transactionsPharmaCyte Biotech, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 365 days, totalling $128.7K.
Net shares · 365d
+160.0K
160.0K buy · 0 sell
Net value · 365d
$128.7K
$128.7K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
6
160.0K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
119.2K sh
Own New
-
Grant·A
Director
$0
119.2K sh
Own New
-
Grant·A
Director
$0
119.2K sh
Own New
-
Grant·A
Director
$0
119.2K sh
Own New
-
Buy·P
Joshua Silverman KEY
CEO and President
$33.3K
40.0K sh · $0.83
Own +11%
-
Buy·P
Director
$16.9K
20.0K sh · $0.84
Own +12%
-
Buy·P
Joshua Silverman KEY
CEO and President
$23.7K
30.0K sh · $0.79
Own +9%
-
Buy·P
Director
$15.8K
20.0K sh · $0.79
Own +13%
-
Buy·P
Joshua Silverman KEY
CEO and President
$23.5K
30.0K sh · $0.78
Own +9%
-
Buy·P
Director
$15.6K
20.0K sh · $0.78
Own +15%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 31, 2026 | Robert Weinstein | Grant A | 119.2K | $0 |
| Mar 31, 2026 | Wayne Remell Walker | Grant A | 119.2K | $0 |
| Mar 31, 2026 | Jonathan Schechter | Grant A | 119.2K | $0 |
| Mar 31, 2026 | Michael M Abecassis | Grant A | 119.2K | $0 |
| Jan 7, 2026 | Joshua Silverman KEY | Buy P | 40.0K | $33.3K |
| Jan 7, 2026 | Jonathan Schechter | Buy P | 20.0K | $16.9K |
| Jan 6, 2026 | Joshua Silverman KEY | Buy P | 30.0K | $23.7K |
| Jan 6, 2026 | Jonathan Schechter | Buy P | 20.0K | $15.8K |
| Jan 5, 2026 | Joshua Silverman KEY | Buy P | 30.0K | $23.5K |
| Jan 5, 2026 | Jonathan Schechter | Buy P | 20.0K | $15.6K |
About PMCB insider trading
This page tracks insider transactions for PharmaCyte Biotech, Inc. (PMCB) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.